Sat, Jan 31, 2015, 1:46 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

CHINA MED TECHS INC ADS Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • madmonsoon2000 madmonsoon2000 Feb 18, 2007 3:07 PM Flag

    Baidu's Mistake

    "factual" statements about the waning of FISH technology?
    To tell you the truth there are very little solid facts are available for you and me from this chinese company! If are in China and you are privy to check their book and CMED's future plans, you are doing fine. I am not! I have to extrapolate possible scenarios based on whatever is available to me. I would not call myself an expert in FISH technology but I know the technology. I do publish scientific papers on peer reviewed journals.

    Why not check this abstract+whole contents!
    http://ajp.amjpathol.org/cgi/content/abstract/157/5/1467

    Technical Advances
    Chromogenic in Situ Hybridization
    A Practical Alternative for Fluorescence in Situ Hybridization to Detect HER-2/neu Oncogene Amplification in Archival Breast Cancer Samples
    Minna Tanner*, David Gancberg{dagger}, Angelo Di Leo{dagger}, Denis Larsimont{dagger}, Ghizlane Rouas{dagger}, Martine J. Piccart{dagger} and Jorma Isola*

    From the Laboratory of Cancer Genetics,*
    Institute of Medical Technology University and University Hospital of Tampere, Tampere, Finland; and the Jules Bordet Institute,{dagger}
    Brussels, Belgium

    Determination of HER-2/neu oncogene amplification has become necessary for selection of breast cancer patients for trastuzumab (Herceptin) therapy. Fluorescence in situ hybridization (FISH) is currently regarded as a gold standard method for detecting HER-2/neu amplification, but it is not very practical for routine histopathological laboratories. We evaluated a new modification of in situ hybridization, the chromogenic in situ hybridization (CISH), which enables detection of HER-2/neu gene copies with conventional peroxidase reaction. Archival formalin-fixed paraffin-embedded tumor tissue sections were pretreated (by heating in a microwave oven and using enzyme digestion) and hybridized with a digoxigenin-labeled DNA probe. The probe was detected with anti-digoxigenin fluorescein, anti-fluorescein peroxidase, and diaminobenzidine. Gene copies visualized by CISH could be easily distinguished with a x40 objective in hematoxylin-stained tissue sections. HER-2/neu amplification typically appeared as large peroxidase-positive intranuclear gene copy clusters. CISH and FISH (according to Vysis, made from frozen pulverized tumor samples) correlated well in a series of 157 breast cancers (kappa coefficient, 0.81). The few different classifications were mostly because of low-level amplifications by FISH that were negative by CISH and immunohistochemistry with monoclonal antibody CB-11. We conclude that CISH, using conventional bright-field microscopy in evaluation, is a useful alternative for determination of HER-2/neu amplification in paraffin-embedded tumor samples, especially for confirming the immunohistochemical staining results.

 
CMEDY.PK
3.400.0000(0.00%)Mar 13 1:43 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Hawaiian Holdings Inc.
NASDAQFri, Jan 30, 2015 4:00 PM EST
Boot Barn Holdings, Inc.
NYSEFri, Jan 30, 2015 4:02 PM EST